Cytek Biosciences Inc
(NAS:CTKB)
$
5.6
0.03 (0.54%)
Market Cap: 735.13 Mil
Enterprise Value: 479.43 Mil
PE Ratio: 0
PB Ratio: 1.87
GF Score: 60/100 - Q1 2024 Cytek Biosciences Inc Earnings Call TranscriptMay 08, 2024$6.27 (-1.72%)Earnings
- Q4 2023 Cytek Biosciences Inc Earnings Call TranscriptFeb 28, 2024$8.74 (-1.24%)Earnings
- Cytek Biosciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Cytek Biosciences Inc Earnings Call TranscriptNov 07, 2023$4.45 (+2.06%)Earnings
- Cytek Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Cytek Biosciences Inc Earnings Call TranscriptAug 08, 2023$8.92 (-2.73%)Earnings
- Cytek Biosciences Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Q1 2023 Cytek Biosciences Inc Earnings Call TranscriptMay 09, 2023$11.67 (+0.60%)Earnings
- Q4 2022 Cytek Biosciences Inc Earnings Call TranscriptFeb 28, 2023$10.3 (-2.28%)Earnings
- Cytek Biosciences Inc To Acquire Flow Cytometry and Imaging Business From DiaSorin- M&A Call TranscriptFeb 13, 2023
- Cytek Biosciences Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Cytek Biosciences Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Q3 2022 Cytek Biosciences Inc Earnings Call TranscriptNov 09, 2022$13.7 (-5.65%)Earnings
- Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Cytek Biosciences Inc Earnings Call TranscriptAug 10, 2022$15.45 (+5.17%)Earnings
- Cytek Biosciences Inc Corporate Analyst Meeting TranscriptJun 22, 2022
- Q1 2022 Cytek Biosciences Inc Earnings Call TranscriptMay 11, 2022$7.41 (-7.84%)Earnings
- Q4 2021 Cytek Biosciences Inc Earnings Call TranscriptFeb 23, 2022$13.12 (-2.53%)Earnings
- Q3 2021 Cytek Biosciences Inc Earnings Call TranscriptNov 08, 2021$25.04 (+1.34%)Earnings
- Cytek Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
Cytek Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 10:20PM GMT
Release Date Price:
$8.38
(-3.23%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon, everyone. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs, and I have the pleasure of introducing the senior management team from Cytek Biosciences. CEO, Wenbin Jiang, to my right; and Patrik Jeanmonod, the CFO. Patrik, Wenbin, thank you very much for joining us today.
Wenbin Jiang
Cytek Biosciences, Inc. - President, CEO & Chairman of the Board
Thank you.
Questions & Answers
Matthew Carlisle Sykes;Wenbin Jiang
Goldman Sachs Group, Inc., Research Division - Research Analyst;Cytek Biosciences, Inc. -
Maybe if you could just sort of start with 2 things. One, maybe for those in the room, introduce who Cytek Biosciences is, just a brief overview of the company and sort of the markets you are involved with; and then two, reflect on Q1 results and sort of what your expectations are as we go into the second half of this year.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)